{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:59:19Z","timestamp":1781283559827,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.biopha.2023.114427","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:02:51Z","timestamp":1677016971000},"page":"114427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immune recovery among Romanian HIV\/AIDS patients receiving darunavir\/ritonavir or darunavir\/cobicistat regimens in cART management: A three-year study"],"prefix":"10.1016","volume":"161","author":[{"given":"Ruxandra-Cristina","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia Mirela","family":"Tit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Andrei","family":"Negru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Flavius","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu Dumitru","family":"Moleriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114427_bib1","doi-asserted-by":"crossref","first-page":"a3172","DOI":"10.1136\/bmj.a3172","article-title":"HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity","volume":"338","author":"Deeks","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2023.114427_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.18683\/germs.2019.1178","article-title":"Consensus statement on the assessment of comorbidities in people living with HIV in Romania","volume":"9","author":"Streinu-Cercel","year":"2019","journal-title":"Germs"},{"key":"10.1016\/j.biopha.2023.114427_bib3","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2021. Available online: \u3008https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf\u3009 (accessed on 2021, March 17)."},{"key":"10.1016\/j.biopha.2023.114427_bib4","unstructured":"Comisia Na\u021bional\u0103 de Lupta Anti-SIDA - Date Statistice, 2020. Available online: \u3008http:\/\/cnlas.ro\/com_jce\/date-statistice.html\u3009 (accessed on 2021, March 03)."},{"key":"10.1016\/j.biopha.2023.114427_bib5","unstructured":"UNAIDS, 2019. Available online: \u3008https:\/\/www.unaids.org\/en\/resources\/fact-sheet\u3009 (accessed on 2021, March 27)."},{"key":"10.1016\/j.biopha.2023.114427_bib6","unstructured":"Ministerul S\u0103n\u0103t\u0103\u0163ii Institutul Na\u0163ional de Boli Infec\u0163ioase, 2019. Available online: \u3008http:\/\/cnlas.ro\/images\/doc\/30062019_rom.pdf\u3009. (accessed on 2021, March 03)."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2023.114427_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12879-016-1397-2","article-title":"Prevalence of osteo-renal impairment in the Romanian HIV cohort","volume":"16","author":"Streinu-Cercel","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002030-199902040-00008","article-title":"Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group","volume":"13","author":"Pakker","year":"1999","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/670957","article-title":"Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions","volume":"2012","author":"Gaardbo","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.biopha.2023.114427_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085613","article-title":"Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease","volume":"9","author":"Emu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114427_bib11","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.biopha.2023.114427_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/cix466","article-title":"CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)","volume":"65","author":"Trickey","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240880","article-title":"Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia","volume":"15","author":"Wolday","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114427_bib14","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/QAD.0000000000002248","article-title":"Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy","volume":"33","author":"Pantazis","year":"2019","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib15","first-page":"382","article-title":"Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence","volume":"2","author":"Dock","year":"2011","journal-title":"Aging Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/aid.2019.0064","article-title":"CD4\/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV","volume":"35","author":"Castilho","year":"2019","journal-title":"AIDS Res Hum. Retrovir."},{"key":"10.1016\/j.biopha.2023.114427_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2023.114427_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tim.2012.09.001","article-title":"Microbial translocation, immune activation, and HIV disease","volume":"21","author":"Klatt","year":"2013","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.biopha.2023.114427_bib19","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/QAD.0000000000000807","article-title":"Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients","volume":"29","author":"Duffau","year":"2015","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/QAD.0b013e32835faa72","article-title":"The CD4\/CD8 ratio as a marker T-cell activation, senescence and activation\/exhaustion in treated HIV-infected children and young adults","volume":"27","author":"Sainz","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.4049\/jimmunol.176.4.2645","article-title":"Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly","volume":"176","author":"Hadrup","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.114427_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/gerona\/60.5.556","article-title":"An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans","volume":"60","author":"Wikby","year":"2005","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"key":"10.1016\/j.biopha.2023.114427_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113077","article-title":"Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat","volume":"150","author":"Marin","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2023.114427_bib24","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.7448\/IAS.17.4.19672","article-title":"Relationship between discordant response to HAART, Tregs, immune activation and low-level viraemia","volume":"17","author":"Saison","year":"2014","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.biopha.2023.114427_bib25","first-page":"9","article-title":"Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir\/Ritonavir or Darunavir\/Cobicistat in Romanian HIV Infected Patients","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2023.114427_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.31688\/ABMU.2021.56.3.05","volume":"56","author":"Marin","year":"2021","journal-title":"Arch. Balk. Med. Union"},{"key":"10.1016\/j.biopha.2023.114427_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-122-8-199504150-00003","article-title":"Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion","volume":"122","author":"Mellors","year":"1995","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.biopha.2023.114427_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/431484","article-title":"Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells\/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(06)70463-7","article-title":"Immunological recovery and antiretroviral therapy in HIV-1 infection","volume":"6","author":"Battegay","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/592113","article-title":"CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy","volume":"47","author":"Khanna","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of Virologic Failure and HIV Drug Resistance","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"2","key":"10.1016\/j.biopha.2023.114427_bib32","first-page":"114","article-title":"CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use","volume":"1989","author":"Taylor","year":"1988","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"6","key":"10.1016\/j.biopha.2023.114427_bib33","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study","volume":"1993","author":"Giorgi","year":"1988","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00126334-200011010-00001","article-title":"The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation","volume":"25","author":"Cohen Stuart","year":"2000","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib35","unstructured":"Guideline for good clinical practice E6(R2). Available online: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-clinical-practice-e6r2\u20134-step-2b_en.pdf\u3009 (accessed on January 16, 2022)."},{"key":"10.1016\/j.biopha.2023.114427_bib36","unstructured":"World Medical Association, 2018. Available online: \u3008https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/\u3009 (accessed on 2021, February 26)."},{"key":"10.1016\/j.biopha.2023.114427_bib37","first-page":"21","article-title":"Darunavir\/cobicistat showing similar effectiveness as darunavir\/ritonavir monotherapy despite lower trough concentrations","author":"Gutierrez-Valencia","year":"2018","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.biopha.2023.114427_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148924","article-title":"Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens","volume":"11","author":"L\u00f3pez-Cort\u00e9s","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114427_bib39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/jac\/dku509","article-title":"Monotherapy with boosted PIs as an ART simplification strategy in clinical practice","volume":"70","author":"Santos","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2023.114427_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037442","article-title":"Antiretroviral simplification with darunavir\/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile","volume":"7","author":"Santos","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114427_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/hiv.12567","article-title":"Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion","volume":"19","author":"Stirrup","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.biopha.2023.114427_bib42","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/00002030-200209270-00002","article-title":"Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease","volume":"16","author":"Valdez","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/510746","article-title":"CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression","volume":"44","author":"Moore","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/511681","article-title":"Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment","volume":"44","author":"Landay","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib45","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/archinte.163.18.2187","article-title":"CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study","volume":"163","author":"Kaufmann","year":"2003","journal-title":"Arch. Intern Med"},{"key":"10.1016\/j.biopha.2023.114427_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13104-017-2602-0","article-title":"Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia","volume":"10","author":"Gezie","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.biopha.2023.114427_bib47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/INF.0b013e3181693892","article-title":"Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression","volume":"27","author":"Paintsil","year":"2008","journal-title":"Pedia Infect. Dis. J."},{"key":"10.1016\/j.biopha.2023.114427_bib48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/QAI.0000000000001843","article-title":"Acute HIV Infection and CD4\/CD8 Ratio Normalization After Antiretroviral Therapy Initiation","volume":"79","author":"Davy-Mendez","year":"2018","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220552","article-title":"Prognostic factors of a lower CD4\/CD8 ratio in long term viral suppression HIV infected children","volume":"14","author":"Guill\u00e9n","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114427_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0000000000002331","article-title":"Effectiveness of Switching to Darunavir\/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The \"STORE\" Study","volume":"84","author":"Gori","year":"2020","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jinf.2012.09.013","article-title":"The CD4\/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression","volume":"66","author":"Serrano-Villar","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2023.114427_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25911","article-title":"CD4\/CD8 ratio, comorbidities, and aging in treated HIV infected individuals on viral suppression","author":"Passos","year":"2020","journal-title":"J. Med Virol."},{"key":"10.1016\/j.biopha.2023.114427_bib53","article-title":"Comparative impact of suppressive antiretroviral regimens on the CD4\/CD8 T-cell ratio: a Cohort study","volume":"95","author":"Masi\u00e1","year":"2016","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.biopha.2023.114427_bib54","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2352-3018(15)00077-6","article-title":"Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study","volume":"2","author":"Rasmussen","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.biopha.2023.114427_bib55","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00002030-200104130-00009","article-title":"Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study","volume":"15","author":"Yamashita","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114427_bib56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1310\/YN11-XJ4L-9YHF-19E4","article-title":"Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals","volume":"2","author":"Touloumi","year":"2001","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.biopha.2023.114427_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood.V96.1.250.013k28_250_258","article-title":"HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism","volume":"96","author":"Lu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114427_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00126334-200108010-00007","article-title":"Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors","volume":"27","author":"Le Moing","year":"2001","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00126334-200106010-00012","article-title":"Increase and plateau of CD4 T-cell counts in the 3(1\/2) years after initiation of potent antiretroviral therapy","volume":"27","author":"Tarwater","year":"2001","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2023.114427_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/08892220150503654","article-title":"Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection","volume":"17","author":"Hejdeman","year":"2001","journal-title":"AIDS Res Hum. Retrovir."},{"key":"10.1016\/j.biopha.2023.114427_bib61","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1086\/315875","article-title":"The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study","volume":"182","author":"DeHovitz","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib62","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1086\/695852","article-title":"The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options","volume":"48","author":"Gazzola","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114427_bib63","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2023.114427_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11904-009-0038-4","article-title":"Early immune senescence in HIV disease","volume":"7","author":"Desai","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.biopha.2023.114427_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamainternmed.2014.4010","article-title":"Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals","volume":"175","author":"Okulicz","year":"2015","journal-title":"JAMA Intern Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223002159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223002159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:19:29Z","timestamp":1781281169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223002159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":65,"alternative-id":["S0753332223002159"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114427","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune recovery among Romanian HIV\/AIDS patients receiving darunavir\/ritonavir or darunavir\/cobicistat regimens in cART management: A three-year study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114427"}}